Skip to content

Advertisement

You're viewing the new version of our site. Please leave us feedback.

Learn more

BMC Gastroenterology

Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

The impact of race and ethnicity on mortality and healthcare utilization in alcoholic hepatitis: a cross-sectional study

  • Folasade P. May1, 2Email author,
  • Vineet S. Rolston3,
  • Elliot B. Tapper4,
  • Ashwini Lakshmanan5,
  • Sammy Saab1, 6 and
  • Vinay Sundaram7
BMC GastroenterologyBMC series – open, inclusive and trusted201616:129

https://doi.org/10.1186/s12876-016-0544-y

Received: 20 February 2016

Accepted: 30 September 2016

Published: 10 October 2016

Abstract

Background

Alcoholic Hepatitis (AH) is major source of alcohol-related mortality and health care expenditures in the United States. There is insufficient information regarding the role of race and ethnicity on healthcare utilization and outcomes for patients with AH. We aimed to determine whether there are racial/ethnic differences in resource utilization and inpatient mortality in patients hospitalized with AH.

Methods

We analyzed data from the Nationwide Inpatient Sample (NIS), years 2008–2011. We calculated demographic, clinical, and healthcare utilization characteristics by race. We then performed logistic regression and generalized linear modeling with gamma distribution (log link), respectively, to determine predictors of inpatient morality and total hospital costs (THC).

Results

We identified 11,304 AH patients from 2008 to 2011. Mean age was 47.0 years, and 62.1 % were male, 61.9 % were white, 9.8 % were black, and 9.7 % were Hispanic. Mean LOS was 6.3 days and significantly longer in whites (6.5 d) than both blacks (5.4 d) and Hispanics (5.9 d). In adjusted models, inpatient mortality was lower for blacks than for whites (adj. OR = 0.50; 95 % CI = 0.32–0.78). THC was significantly higher for Hispanics than whites (fold increase = 1.25; 95 % CI = 1.01–1.49).

Conclusions

We identified differences in healthcare utilization and mortality by race/ethnicity. THC was significantly higher among Hispanics than for whites and blacks. We also demonstrated lower inpatient mortality in blacks compared to whites. These variations may implicate racial and ethnic differences in access to care, quality of care, severity of AH on presentation, or other factors.

Keywords

Liver diseaseNationwide inpatient sampleDisparitiesHealthcare utilizationAlcoholic hepatitis

Background

Alcoholic hepatitis (AH) is a major cause of alcohol-related morbidity and mortality in the United States (U.S.) [1, 2]. Characterized by acute liver inflammation in the setting of chronic alcohol use, AH carries a poor prognosis with a 30-day mortality as high as 30 %, depending on the severity of disease [35]. AH also poses significant burden on healthcare utilization and costs in the U.S. National data demonstrate that inpatient healthcare expenditures associated with AH may exceed spending for other chronic liver disease states, including hepatitis C (HCV) and hepatocellular carcinoma (HCC) [1, 6, 7]. As effective treatment is lacking for this condition, the mortality, healthcare costs, and utilization related to AH are unlikely to improve in the near future.

There is increasing emphasis on improving health equity and addressing healthcare disparities regarding race and ethnicity in the U.S. [8]. Current literature documents racial and ethnic disparities in mortality, prevalence, and healthcare utilization in several chronic liver disease states [913]. For example, blacks are less likely than white Americans to undergo screening for HCV and more likely than white Americans to die from HCV-related complications [11]. Studies have similarly demonstrated Hispanic Americans to have a greater prevalence of non-alcoholic fatty liver disease and an increased risk of developing HCC when compared to caucasians and blacks [9, 10, 12, 13].

While racial/ethnic variation in healthcare outcomes and utilization has been explored in many chronic liver disease states, there is a paucity of literature regarding the impact of these factors in relation to alcoholic hepatitis [14]. In this study, we aimed to determine whether there are racial and ethnic differences in inpatient mortality and health service utilization among patients hospitalized for AH in the U.S, using a large nationwide database.

Methods

Source of data

We performed a retrospective cross-sectional study using the Nationwide Inpatient Sample (NIS), years 2008–2011 [15]. The NIS is the largest publicly available inpatient database and includes a 20 % stratified sample of all U.S. inpatient discharges occurring in a given year from approximately 1000 non-federal U.S. hospitals in 42 to 47 states, depending on the year. Each hospital included in the NIS participates in the Agency for Healthcare Research and Quality Healthcare Cost and Utilization Project. Each discharge record from the NIS contains associated patient and hospital demographic information, primary and up to 24 secondary discharge diagnoses, and up to 15 procedural codes. The study protocol was approved as exempt from review by the institutional review board of Cedars-Sinai Medical Center.

Study population

The study sample included inpatients age 18 years or older with a primary discharge diagnosis of AH. As per previously published studies utilizing administrative data to identify patients with AH, we used the International Classification of Diseases, 9th revision, Clinical Modification (ICD-9-CM) code 571.1 to identify our AH sample [2, 16].

Variables

Our main outcomes were inpatient mortality, total hospital costs (THC), length of hospital stay (LOS), and number of procedures performed (NPR). THCs were inflated to 2011 values for years 2008, 2009, and 2010 using the consumer price index (CPI) [7]. We also accounted for inpatient procedures used in the management of AH, including nasogastric intubation (NGT), mechanical ventilation (MV), hemodialysis, esophagogastroduodenoscopy (EGD), paracentesis, liver biopsy, and liver transplantation.

Additional patient-level data included patient age, sex, race/ethnicity, socioeconomic status (SES), insurance type (Medicare, Medicaid, private, self-pay, other), comorbidity, source of admission (emergency room (ER), hospital transfer, other health-related facility, other non-health facility), and disposition at discharge (home or home with aid, other health facility, and other). For SES, we used income strata. For race, categories included white, black, Hispanic, and other (Asian, Pacific islander, Native American, or another race). Hospital characteristics in the analysis included hospital region (Northeast, South, Midwest, West), hospital type (teaching, nonteaching), and hospital setting (urban, rural).

We used the Deyo modification of the Charlson index as a proxy for patient comorbidity [17, 18]. We stratified the Charlson index into 3 groups to represent the degree of comorbidity: Mild (score = 0), moderate (score = 1–3), and severe (score > 3). In addition, we used the Baveno IV consensus criteria as a measure for severity of liver disease, where patients were categorized as stage 1 (no esophageal varices or ascites), stage 2 (esophageal varices, no ascites or bleeding), stage 3 (ascites, with or without esophageal varices), or stage 4 (history of gastrointestinal bleeding with or without ascites) [19]. Stage 1 and 2 disease represented compensated cirrhosis; stage 3 and 4 disease represented decompensated cirrhosis. As greater than 90 % of patients with biopsy-proven AH have underlying liver cirrhosis, this classification system is applicable to our study population [20].

We also accounted for known conditions that might impact AH outcomes, including ascites, HCV infection, gastrointestinal bleeding, hepatic encephalopathy, and bacterial infection (ICD-9 codes are provided in Additional file 1: Table S1) [21]. For infection, we created one variable that included all ICD-9-CM codes for bacterial infections potentially treated with antibiotics, similar to methodology used in previously published studies (ICD-9 codes are provided in Additional file 1: Table S1) [16, 22].

Statistical analyses

We described patient descriptive and clinical characteristics as means with standard deviation or medians with interquartile ranges for Gaussian and non-Gaussian distributed variables, respectively. For crude statistical comparisons, we used the chi-square test for categorical variables, student’s t-test and one-way analysis of variance (ANOVA) with the Tukey-Kramer method to compare continuous variables, and the Wilcoxon-Rank sum test for non-Gaussian distributed variables, all with the Bonferroni correction for multiple comparisons. For THC, LOS and NPR, we computed regional comparisons of means by quantile regression.

Following descriptive analyses, we determined significant predictors of inpatient mortality and THC among patients admitted to U.S. hospitals with AH. We used multiple imputation for missing values for hospital admission source (19 % missing), discharge disposition (14 % missing), and race (14 % missing) using 20 imputed datasets. Other missing values were less than 5 % and were not imputed [23]. For mortality, we used logistic regression, controlling for patient demographic and clinical factors, to determine the impact of race/ethnicity on inpatient mortality among patients admitted with a primary diagnosis of AH. Second, we performed a generalized linear model (GLM) with gamma distribution and log link to examine the relationship between race/ethnicity and THC. GLM was felt appropriate in the present analysis given that THC is a heavily skewed, non-integer outcome. GLM compares the log of THC across groups while controlling for covariates in the model. Thus, the antilog of the parameters of the linear regression model can be interpreted as the fold increase in THC between groups being compared. For both regression models, covariates were selected based on significance in univariate analysis at the p <0.05 level or clinical experience and consistent prior data supporting their association. We used southern region as the reference geographic region as it was the region with the lowest mean value for THC based on unadjusted analysis.

Analyses were performed with STATA 13.1 software (Stata Corp, College Station, TX) with the appropriate survey estimation commands and strata weights provided in each NIS file. To represent national population estimates, we applied survey weights to the patient-level observations in the dataset. A p-value less than 0.05 on two-tailed testing was considered significant except in cases where the Bonferroni correction was indicated.

Results

Characteristics of study population

Table 1 provides demographic and clinical characteristics of the study sample of 11,304 AH patients, stratified by geographic region. Most of the patients were white (61.9 %), followed by black (9.8 %), and Hispanic (9.7 %). Mean age at admission was slightly lower in the Hispanic population (43.7 years) than in the white group (47.5 years; p < 0.01) and black group (48.2 y; p < 0.01). The majority of patients were white and male in each region.
Table 1

Demographic and clinical characteristics of patients hospitalized with alcoholic hepatitis from 2008–2011; N = 11,304a,b

Parameter

White n = 7019 (61.9 %)

Black n = 1103 (9.8 %)

Hispanic n = 1088 (9.7 %)

Other n = 548 (4.9 %)

Totala

Male Sex (%)

4093 (58.4)

665 (60.4)

894 (82.3)

378 (69.2)

7015 (62.1)

Mean Age, y (s.d)

47.5 (11.0)

48.2 (10.5)

43.7 (11.1)

44.8 (11.6)

47.0 (11.0)

Income (%)

 0–25 %

1428 (20.4)

607 (55.4)

366 (33.9)

177 (32.8)

3062 (27.2)

 26–50 %

1845 (26.3)

223 (20.0)

248 (22.8)

102 (18.8)

2874 (25.4)

 51–75 %

1837 (26.2)

147 (13.3)

250 (22.4)

110 (19.7)

2703 (23.8)

 76–100 %

1707 (24.3)

78 (7.0)

157 (14.7)

117 (20.9)

2278 (20.1)

Payer (%)

 Medicare

972 (13.9)

191 (17.3)

103 (9.5)

58 (10.3)

1549 (13.7)

 Medicaid

1345 (19.2)

338 (30.9)

301 (28.0)

163 (29.8)

2500 (22.2)

 Private

2412 (34.4)

193 (17.3)

204 (18.6)

142 (25.9)

3441 (30.5)

 Self-pay

1605 (22.7)

298 (26.9)

330 (30.4)

126 (23.1)

2703 (23.8)

 Other

661 (9.3)

75 (6.9)

149 (13.4)

58 (10.9)

1063 (9.4)

Admission Source (%)

 Emergency room

1449 (20.3)

168 (15.1)

409 (37.2)

105 (18.7)

2238 (19.6)

 Outside hospital

63 (0.9)

2 (0.2)

15 (1.4)

8 (1.4)

94 (0.8)

 Non-health facility

16 (0.2)

2 (0.2)

0 (0.0)

2 (0.4)

21 (0.2)

 Other health facility

477 (6.8)

103 (9.3)

48 (4.4)

32 (5.7)

693 (6.7)

 Source unknown

5014 (71.8)

828 (75.2)

616 (57.1)

401 (73.9)

8258 (73.3)

Disposition (%)

 Home/Home with aid

4821 (68.8)

849 (77.3)

656 (60.8)

392 (71.8)

7927 (70.3)

 Other inpatient facility

746 (10.7)

73 (6.7)

51 (4.7)

34 (6.3)

1115 (9.9)

 Other

440 (6.3)

34 (3.1)

42 (3.9)

36 (6.7)

669 (5.9)

 Unknown

1012 (14.3)

147 (12.9)

339 (30.5)

86 (15.3)

1593 (13.9)

 Mean Charlson Index Score (s.d.)

1.7 (1.9)

1.4 (1.8)

1.6 (1.8)

1.6 (1.9)

1.6 (1.8)

Severity of Liver Disease (%)

 No cirrhosis

4913 (70.1)

869 (78.7)

773 (67.2)

377 (69.0)

8007 (70.9)

 Compensated Cirrhosis

981 (13.9)

139 (12.7)

192 (17.8)

76 (13.8)

1608 (14.2)

 Decompensated Cirrhosis

1125 (16.0)

95 (8.6)

163 (15.0)

95 (17.2)

1689 (14.9)

 Known Hepatitis C (%)

556 (7.9)

121 (10.0)

87 (8.2)

35 (6.3)

921 (8.1)

 Sepsis (%)

199 (2.9)

27 (2.4)

24 (2.2)

13 (2.4)

294 (2.6)

 Gastrointestinal Bleed (%)

126 (1.8)

22 (2.0)

31 (2.9)

13 (2.3)

241 (2.1)

 Ascites (%)

2030 (28.9)

165 (15.0)

251 (23.2)

161 (29.3)

3027 (26.7)

 Hepatic Encephalopathy (%)

1066 (15.1)

90 (8.1)

126 (11.5)

65 (11.9)

1602 (14.1)

 Any infection (%)

1792 (25.6)

226 (20.5)

222 (20.1)

128 (23.5)

2756 (24.3)

Hospital Type/Setting (%)

 Teaching

2947 (42.4)

646 (59.6)

597 (56.4)

289 (55.4)

5283 (47.4)

 Urban

6209 (89.7)

994 (91.8)

1041 (97.0)

471 (89.8)

10014 (89.9)

U.S. Hospital Region (%)

 Northeast

1610 (23.5)

293 (27.4)

250 (23.5)

123 (22.4)

2314 (20.9)

 Midwest

1118 (16.0)

180 (16.3)

76 (7.1)

82 (14.9)

2387 (21.2)

 South

2614 (37.0)

527 (47.3)

313 (28.6)

146 (26.2)

3969 (34.8)

 West

1677 (23.5)

103 (9.1)

449 (40.9)

197 (36.6)

2634 (23.1)

Other race refers to subjects with Asian, Pacific islander, Native American, or another race

y years

aRace/ethnicity was unknown for 1546 individuals not included in this table

bData presented as unweighted n (weighted %) or mean (s.d.)

Weighted % in columns add to 100 %

Notably, over 50 % of blacks with AH were in the lowest quintile of income (55.4 %). In both blacks and Hispanics, Medicaid and self-pay (no insurance) were the most common insurance/payer status. There were also significant racial/ethnic differences in clinical characteristics. Blacks with AH were more likely than whites with AH to carry a diagnosis of HCV (10.0 % v 7.9 %; p < 0.01). Hispanics with AH were more likely than whites with AH to have a gastrointestinal bleed during hospitalization (2.9 % v. 1.8 %; p < 0.01). Decompensated cirrhosis was more common in whites with AH (16.0 %) and Hispanics with AH (15.0 %) than in blacks with AH (8.6 %).

Outcomes and resource utilization

As demonstrated in Table 2, there were differences in utilization of hospital resources by race/ethnicity. Mean THC over the course of an inpatient hospitalization was significantly higher among Hispanics ($42,387) than among blacks ($33,359; p < 0.01). Mean LOS was longer among whites (6.5 d) compared to blacks (5.4 d) and Hispanics (5.9 d). The mean aggregate number of inpatient procedures performed was higher among whites than blacks (1.3 v. 1.1, p < 0.01) but similar between whites and Hispanics (1.3 v. 1.3, p = 0.16). Inpatient hospital mortality was lowest for blacks (2.3 %) and significantly lower in this racial group than for whites (4.5 %) (p<0.01) and Hispanics (3.9 %) (p<0.01). Only 4 liver transplants were reported in the entire sample. Given this low number, we did not compare this outcome by race/ethnicity.
Table 2

Healthcare utilization and mortality outcomes by race/ethnicitya,b

 

White

Black

Hispanic

Other

Total

P value

W v B

P value

W v H

P value

B v H

THC, $

 Mean

38,965.68

33,358.73

42,386.95

42,032.85

37,978.69

<0.01

0.09

<0.01

 Median

23,399.00

20,585.54

25,530.00

24,094.00

23,020.00

 (IQR)

(41,903–13,915)

(37,782–11,944)

(43,287–15,110)

(44,952–13,444)

(40,607–13,501)

LOS, d

 Mean

6.5

5.4

5.9

6.9

6.3

<0.01

0.01

0.04

 Median

4

4

4

4

4

 (IQR)

(8–3)

(7–2)

(7–2)

(8–3)

(8–3)

NPR

 Mean

1.3

1.1

1.3

1.5

1.3

<0.01

0.21

0.16

 Median

1

0

1

1

1

 (IQR)

(2–0)

(1–0)

(2–0)

(2–0)

(2–0)

 Nasogastric tube (%)

26 (0.3)

3 (0.3)

5 (0.5)

2 (0.4)

43 (0.4)

0.67

0.60

0.48

 Mechanical Ventilation (%)

241 (3.4)

34 (3.1)

34 (3.1)

24 (4.5)

385 (3.4)

0.54

0.62

0.93

 Hemodialysis (%)

3 (<0.1)

0 (0)

1 (<0.1)

1 (0.2)

8 (<0.1)

--

0.53

--

 Liver biopsy (%)

241 (3.4)

34 (3.2)

27 (2.5)

14 (3.1)

355 (3.2)

0.68

0.10

0.32

 Paracentesis (%)

1259 (17.8)

103 (9.2)

154 (14.2)

94 (17.2)

1887 (16.6)

<0.001

<0.001

<0.001

 EGD (%)

1111 (15.9)

153 (13.7)

161 (14.8)

86 (15.7)

1784 (15.8)

0.06

0.40

0.43

 Deaths (%)

315 (4.5)

25 (2.3)

43 (3.9)

29 (5.3)

489 (4.3)

<0.001

0.38

0.03

Other race refers to subjects with Asian, Pacific islander, Native American, or another race

W white, B black, H hispanic, THC total hospital costs, LOS length of stay, NPR number of procedures, IQR interquartile range, EGD esophagogastroduodenoscopy

aTotal hospital costs for 2008, 2009, and 2010 are inflated to 2011 values

b% values are weighted to national population estimates

-- there were no black subjects with hemodialysis

Predictors of inpatient mortality

Table 3 provides significant predictors of inpatient mortality for hospitalized patients with AH in controlled models. Blacks were significantly less likely than whites to die while hospitalized for AH (adjusted OR = 0.50; 95 % CI = 0.32–0.78). Hispanics and whites had similar inpatient mortality. Additional significant predictors of inpatient mortality included increasing age, increasing Charlson index, severe cirrhosis, and greater than zero inpatient procedures performed during the current admission (Table 3).
Table 3

Predictors of inpatient mortality in patients with AH

Predictor

Died % (n = 489)

Odds Ratio (95 % CI)

Age

--

1.02 (1.01–1.03)***

Sex

 Male

322 (4.6)

Reference

 Female

167 (3.9)

0.83 (0.67–1.01)

Race/Ethnicity

 White

315 (4.5)

Reference

 Black

25 (2.3)

0.50 (0.32–0.78)**

 Hispanic

43 (3.9)

0.89 (0.61–1.30)

 Other

29 (5.3)

1.07 (0.70–1.66)

Income

  

 Lowest 25 %

139 (4.5)

1.21 (0.92–1.60)

 25–50 %

122 (4.3)

Reference

 50–75 %

117 (4.3)

1.06 (0.81–1.38)

 75–100 %

97 (4.3)

0.87 (0.65–1.16)

Charlson comorbidity

--

1.41 (1.34–1.49)***

Severity of liver disease

 No cirrhosis

260 (3.3)

Reference

 Stage 1–2

78 (4.9)

0.79 (0.58–1.07)

 Stage 3–4

151 (9.0)

0.77 (0.59–0.99)*

Teaching Hospital

 

 No

234 (4.0)

0.96 (0.77–1.20)

 Yes

245 (4.6)

Reference

Hospital setting

 Urban

432 (4.3)

Reference

 Rural

47 (4.2)

0.89 (0.62–1.28)

Number of Procedures

 0

Reference

 

 1

54 (1.9)

1.53 (1.03–2.23)*

 2

54 (3.8)

2.79 (1.83–4.25)***

  > 2

332 (17.4)

13.3 (9.57–18.41)***

Data are presented as n (%) or odds ratios (95 % CI)

Final logistic regression model included survey weights and the following variables: sex, age, race/ethnicity, income, Charlson comorbidity score, severity of liver disease, teaching hospital status, hospital location, and number of inpatient procedures

Other race refers to subjects with Asian, Pacific islander, Native American, or another race

CI confidence interval

*P <0.05; **P <0.01; ***P <0.001

Predictors of total hospital costs

Table 4 provides results for the predictor model for THC. When controlling for demographic and clinical factors, Hispanic ethnicity was associated with a 1.25-fold increase in THC when compared to white race. Thus, on average, a Hispanic patient admitted with AH had a THC 125 % that of a white patient admitted for the same duration of time. Despite this difference in whites and Hispanics, the THC in blacks was comparable to the THC in whites. Age, income, payer status, Charlson index, NPR, and hospitalization in the western U.S. were also significant predictors of inpatient costs.
Table 4

Predictors of inpatient THC in patients with AH

Predictor

Factor (fold increase)

95 % Confidence Interval

Age

0.99

0.98–0.99*

Sex

 Male

Reference

 

 Female

1.03

0.94–1.15

Race/Ethnicity

 White

Reference

 

 Black

1.24

0.96–1.60

 Hispanic

1.25

1.01–1.49*

 Other

0.94

0.79–1.13

Income

 

 Lowest 25 %

0.93

0.76–1.13

 25–50 %

Reference

 

 50–75 %

1.07

0.92–1.25

 75–100 %

1.18

1.03–1.34*

Payer

 Medicaid

0.85

0.73–0.98*

 Medicare

0.94

0.81–1.09

 Private

Reference

 

 Self-pay

0.75

0.62–0.91**

 Other

0.84

0.72–0.99*

 Length of Stay

1.02

1.02–1.03***

 Charlson Index

1.04

1.02–1.07***

Severity of liver disease

 No cirrhosis

Reference

 

 Stage 1–2

1.12

0.97–1.31

 Stage 3–4

1.01

0.89–1.15

Number of Procedures

 

 0

Reference

 

 1

1.27

1.20–1.34***

 2

1.74

1.53–1.99***

  > 2

2.97

2.72–3.25***

Hospital Region

 Northeast

Reference

 

 Midwest

1.06

0.85–1.33

 South

0.88

0.70–1.11

 West

1.32

1.02–1.71*

Teaching Hospital

 No

Reference

 

 Yes

1.10

0.94–1.28

Hospital setting

 Urban

1.28

1.11–1.48***

 Rural

Reference

 

Parameter coefficients are presented as a fold increase with 95 % CI

Final general linear model included survey weights and the following, variables: age, sex, race/ethnicity, income, payer, length of inpatient stay, Charlson comorbidity score, severity of liver disease, hospital region, teaching hospital status, hospital location, and number of inpatient procedures

Other race refers to subjects with Asian, Pacific islander, Native American, or another race

CI confidence interval

*P <0.05; **P <0.01; ***P <0.001

Discussion

The cost of care and high resource utilization associated with AH is significant as demonstrated both in our study and in previous analyses [1]. However, there is currently little knowledge about variation in healthcare utilization and outcomes by race and ethnicity in this condition. This study of a nationally representative sample of hospitalized patients with AH contributes several novel findings regarding the relationships between race, outcomes and resource utilization. First, we demonstrated a higher average THC among Hispanics than whites and blacks. Secondly, we identified black race as an independent predictor for lower inpatient mortality compared to white race in patients hospitalized with AH.

Hispanic patients were shown to incur the highest charges in the nation, at 1.25 times higher than whites after adjusting for other factors including SES and payer source. These results are consistent with previous findings regarding other disease states that identified an association between Hispanic ethnicity and increased in-hospital service utilization, particularly for conditions characterized by organ failure and end-of-life [2426]. Prior studies have further demonstrated that undocumented and uninsured Americans have poor access to timely medical care, particularly Hispanics who disproportionately live below the poverty line [27], and who may face exposure to unhealthy social and physical environments and lack of access to healthcare services [2833]. Pervasive disparities in access to preventive services and primary care [29, 30, 32], as well as presentation with late-stage disease [3436], likely contribute to increased resource utilization during inpatient hospitalization among Hispanics.

Differential use of the emergency room (ER) may also partially explain our findings of higher THC in Hispanics. We found that Hispanics utilized the ER as the source of admission significantly more frequently than whites or blacks. Consistent with other studies, ER-based referrals for inpatient hospitalizations are associated with higher THC [37]. Additionally, Hispanic patients who report alcohol use utilize ER services for the care of alcohol related consequences such as AH more commonly than non-Hispanics [3840].

The finding that black patients with AH had lower adjusted mortality compared to other racial/ethnic groups is also notable. One possible explanation for this finding is that blacks do not have as severe a presentation of AH as compared to other race/ethnic groups. Previous findings from a single-center investigation demonstrated blacks (0 %) had a significantly lower proportion of patients presenting with severe AH, defined as discriminant function > 32, when compared to whites (39 %) and Hispanics (57 %) [14]. Although this previous study did not examine inpatient mortality, it can be inferred that the milder disease presentation among blacks would lead to a lower rate of death during hospitalization [14]. Our study, using a nationwide database, may support this hypothesis. Another explanation for lower inpatient mortality among blacks may be related to differences in provider care patterns between blacks and non-blacks. Studies in the literature have demonstrated lower inpatient mortality in blacks compared to whites for several conditions, which may be due to variation in quality of care or disease management and, possibly, earlier discharge and/or greater out of hospital mortality among blacks [4143]. Our data source limited our ability to investigate these hypotheses; however, future studies should explore these potential explanations.

Our data must be interpreted in the context of the study’s limitations. First, NIS does not provide access to anthropometric or laboratory data. Such limitations might explain the relatively low rate of HCV seen in our AH cohort as HCVAb and HCV-RNA status may not have been known for all study subjects. It also limited us from distinguishing between non-severe AH and severe AH by calculating a discriminant function. However, we were able to account for comorbid medical conditions and severity of hepatic decompensation using the Charlson comorbidity score and Baveno IV measure. In doing so, we aimed to control for overall co-morbidity and liver disease severity, regardless of etiology. An additional limitation in our study was the inability to make conclusions about resource utilization and mortality for members of small race/ethnic groups (Asians, Pacific Islanders, Native Americans). As each of these groups was small, they were combined to create a heterogeneous ‘other race’ category. As a result, we were unable to analyze each of these groups separately. Lastly, as our study is a cross-sectional, observational study based on secondary data, we are unable to make conclusions about causation. These limitations are mitigated, however, by use of a large, nationally-representative database that enhances the generalizability of our results. Based on our findings, we suggest additional analyses to assess physician practice patterns in the management of AH patients, with attention to explanations for why racial and ethnic differences in mortality and resource utilization exist.

Conclusions

In conclusion, our study demonstrated significant variation in inpatient mortality and inpatient costs between whites and racial/ethnic minorities hospitalized for AH in the U.S. Hispanics admitted for AH had similar mortality to but higher associated costs than whites admitted for AH. Blacks hospitalized for AH had lower inpatient mortality but similar inpatient costs to whites hospitalized for the same condition. We suspect that the differences in morality, cost, and resource utilization observed reflect multiple factors, including differences in access to care, comorbidity, AH severity at presentation, and quality of care delivered. Further investigation is warranted regarding the specific patient-, provider-, and system-level factors driving these findings to improve clinical outcomes, improve health equity, and curtail high healthcare costs.

Abbreviations

AH: 

Alcoholic hepatitis

CPI: 

Consumer price index

EGD: 

Hemodialysis, esophagogastroduodenoscopy

ER: 

Emergency room

ICD-9 CM: 

International Classification of Diseases, 9th revision, Clinical Modification

IQR: 

Interquartile range

LOS: 

Length of stay

MV: 

Mechanical ventilation

NGT: 

Nasogastric intubation

NIS: 

Nationwide Inpatient Sample

NPR: 

Number of procedures

SES: 

Socioeconomic status

THC: 

Total hospital charges

US: 

United States

Declarations

Acknowledgements

We would like to acknowledge the UCLA Institute for Digital Research and Education for their assistance with the statistical analysis included in this manuscript.

Funding

This research was supported by the NIH Training grant (T32DK07180—40) for Dr. May.

Availability of data and materials

The datasets supporting the conclusions of this article are publically available from the Agency for Healthcare Research and Quality (AHRQ), https://www.hcup-us.ahrq.gov/nisoverview.jsp.

Authors’ contributions

FM: study concept and design, conceptual model, analysis and interpretation of data, drafting of the manuscript, critical revision of the manuscript. ET: drafting and critical revision of the manuscript. VS: study concept and design, drafting of the manuscript, critical revision of the manuscript. AL: study concept and design, analysis and interpretation of the data, critical revision of the manuscript. SS: critical revision of the manuscript. VS: study concept and design, conceptual model, analysis and interpretation of data, drafting of the manuscript, critical revision of the manuscript, study supervision.

Competing interests

Folasade P. May, MD, PhD: None

Vineet S. Rolston, MD: None

Elliot B. Tapper, MD: None

Ashwini Lakshmanan, MD, MPH: None

Sammy Saab, MD, MPH: None

Vinay Sundaram, MD, MSC: None

Consent for publication

Not applicable.

Ethics approval and consent to participate

The study protocol was approved as exempt from review by the institutional review board of Cedars-Sinai Medical Center.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Division of Digestive Diseases, Department of Medicine, David Geffen School of Medicine at UCLA
(2)
Department of Health Policy and Management, UCLA Fielding School of Public Health
(3)
Department of Medicine, Cedars-Sinai Medical Center
(4)
Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School
(5)
Department of Pediatrics, Center for Fetal and Neonatal Medicine, Children’s Hospital Los Angeles, Keck School of Medicine, University of Southern California
(6)
Department of Surgery, David Geffen School of Medicine at UCLA
(7)
Division of Gastroenterology and Hepatology and Comprehensive Transplant Center, Cedars-Sinai Medical Center

References

  1. Jinjuvadia R, Liangpunsakul S, Consortium ftTRaEAHT. Trends in Alcoholic Hepatitis-related Hospitalizations, Financial Burden, and Mortality in the United States. J Clin Gastroenterol. 2015;49(6):506–11.Google Scholar
  2. Liangpunsakul S. Clinical characteristics and mortality of hospitalized alcoholic hepatitis patients in the United States. J Clin Gastroenterol. 2011;45(8):714–9.View ArticlePubMedPubMed CentralGoogle Scholar
  3. Basra S, Anand BS. Definition, epidemiology and magnitude of alcoholic hepatitis. World J Hepatol. 2011;3(5):108–13.View ArticlePubMedPubMed CentralGoogle Scholar
  4. Maddrey WC, Boitnott JK, Bedine MS, Weber Jr FL, Mezey E, White Jr RI. Corticosteroid therapy of alcoholic hepatitis. Gastroenterology. 1978;75(2):193–9.PubMedGoogle Scholar
  5. Thursz MR, Richardson P, Allison M, Austin A, Bowers M, Day CP, Downs N, Gleeson D, MacGilchrist A, Grant A, et al. Prednisolone or pentoxifylline for alcoholic hepatitis. N Engl J Med. 2015;372(17):1619–28.View ArticlePubMedGoogle Scholar
  6. Mishra A, Otgonsuren M, Venkatesan C, Afendy M, Erario M, Younossi ZM. The inpatient economic and mortality impact of hepatocellular carcinoma from 2005 to 2009: analysis of the US nationwide inpatient sample. Liver Int. 2013;33(8):1281–6.View ArticlePubMedGoogle Scholar
  7. Younossi ZM, Otgonsuren M, Henry L, Arsalla Z, Stepnaova M, Mishra A, Venkatesan C, Hunt S. Inpatient resource utilization, disease severity, mortality and insurance coverage for patients hospitalized for hepatitis C virus in the United States. J Viral Hepat. 2015;22(2):135–43.View ArticleGoogle Scholar
  8. Institute of Medicine (IOM). Crossing the Quality Chasm. Crossing the Quality Chasm: A New Health System for the 21st Century. Washington, D.C: National Academy Press; 2001.Google Scholar
  9. Carrion AF, Ghanta R, Carrasquillo O, Martin P. Chronic liver disease in the Hispanic population of the United States. Clin Gastroenterol Hepatol. 2011;9(10):834–41. quiz e109-810.View ArticlePubMedPubMed CentralGoogle Scholar
  10. El-Serag HB, Kramer J, Duan Z, Kanwal F. Racial differences in the progression to cirrhosis and hepatocellular carcinoma in HCV-infected veterans. Am J Gastroenterol. 2014;109(9):1427–35.View ArticlePubMedGoogle Scholar
  11. Saab S, Jackson C, Nieto J, Francois F. Hepatitis C in African Americans. Am J Gastroenterol. 2014;109(10):1576–84. quiz 1575, 1585.View ArticlePubMedGoogle Scholar
  12. Saab S, Manne V, Nieto J, Schwimmer JB, Chalasani NP. Nonalcoholic Fatty Liver Disease in Latinos. Clin Gastroenterol Hepatol. 2016;14(1):5–12.Google Scholar
  13. Schneider AL, Lazo M, Selvin E, Clark JM. Racial differences in nonalcoholic fatty liver disease in the U.S. population. Obesity. 2014;22(1):292–9.View ArticlePubMedGoogle Scholar
  14. Levy RE, Catana AM, Durbin-Johnson B, Halsted CH, Medici V. Ethnic differences in presentation and severity of alcoholic liver disease. Alcohol Clin Exp Res. 2015;39(3):566–74.View ArticlePubMedPubMed CentralGoogle Scholar
  15. Healthcare Cost and Utilization Project (HCUP). Content last reviewed September 2016. Rockville, MD: Agency for Healthcare Research and Quality. http://www.ahrq.gov/research/data/hcup/index.html.
  16. Sundaram V, May FP, Manne V, Saab S. Effects of Clostridium difficile infection in patients with alcoholic hepatitis. Clin Gastroenterol Hepatol. 2014;12(10):1745–52. e1742.View ArticlePubMedPubMed CentralGoogle Scholar
  17. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–83.View ArticlePubMedGoogle Scholar
  18. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613–9.View ArticlePubMedGoogle Scholar
  19. D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol. 2006;44(1):217–31.View ArticlePubMedGoogle Scholar
  20. Mathurin P, Louvet A, Duhamel A, Nahon P, Carbonell N, Boursier J, Anty R, Diaz E, Thabut D, Moirand R, et al. Prednisolone with vs without pentoxifylline and survival of patients with severe alcoholic hepatitis: a randomized clinical trial. JAMA. 2013;310(10):1033–41.View ArticlePubMedGoogle Scholar
  21. Louvet A, Wartel F, Castel H, Dharancy S, Hollebecque A, Canva-Delcambre V, Deltenre P, Mathurin P. Infection in patients with severe alcoholic hepatitis treated with steroids: early response to therapy is the key factor. Gastroenterology. 2009;137(2):541–8.View ArticlePubMedGoogle Scholar
  22. Ali M, Ananthakrishnan AN, Ahmad S, Kumar N, Kumar G, Saeian K. Clostridium difficile infection in hospitalized liver transplant patients: a nationwide analysis. Liver Transplant. 2012;18(8):972–8.View ArticleGoogle Scholar
  23. Little RJA, Rubin DB. Statistical analysis with missing data. 2nd ed. Hoboken: Whiley-InterScience; 2002.Google Scholar
  24. Barnato AE, Chang C-CH, Saynina O, Garber AM. Influence of race on inpatient treatment intensity at the end of life. J Gen Intern Med. 2007;22(3):338–45.View ArticlePubMedPubMed CentralGoogle Scholar
  25. Hanchate A, Kronman AC, Young-Xu Y, Ash AS, Emanuel E. Racial and ethnic differences in end-of-life costs: why do minorities cost more than whites? Arch Intern Med. 2009;169(5):493–501.View ArticlePubMedPubMed CentralGoogle Scholar
  26. Propper B, Black 3rd JH, Schneider EB, Lum YW, Malas MB, Arnold MW, Abularrage CJ. Hispanic ethnicity is associated with increased costs after carotid endarterectomy and carotid stenting in the United States. J Surg Res. 2013;184(1):644–50.View ArticlePubMedGoogle Scholar
  27. Proctor D-WaB. Income and Poverty in the United States: 2013. In: United States Census Bureau UDoC, editor. Economics and Statistics Administration. Washington D.C: U.S. Government Printing Office; 2014. p. 60–249.Google Scholar
  28. Rodgers JT, Purnell JQ. Healthcare navigation service in 2-1-1 San Diego: guiding individuals to the care they need. Am J Prev Med. 2012;43(6 Suppl 5):S450–6.View ArticlePubMedGoogle Scholar
  29. Winkleby MA, Cubbin C. Influence of individual and neighbourhood socioeconomic status on mortality among black, Mexican-American, and white women and men in the United States. J Epidemiol Community Health. 2003;57(6):444–52.View ArticlePubMedPubMed CentralGoogle Scholar
  30. Adler NE, Newman K. Socioeconomic disparities in health: pathways and policies. Health Aff. 2002;21(2):60–76.View ArticleGoogle Scholar
  31. Hanson MD, Chen E. Socioeconomic status and health behaviors in adolescence: a review of the literature. J Behav Med. 2007;30(3):263–85.View ArticlePubMedGoogle Scholar
  32. Phelan JC, Link BG, Tehranifar P. Social conditions as fundamental causes of health inequalities: theory, evidence, and policy implications. J Health Soc Behav. 2010;51(Suppl):S28–40.View ArticlePubMedGoogle Scholar
  33. Krueger PM, Chang VW. Being poor and coping with stress: health behaviors and the risk of death. Am J Public Health. 2008;98(5):889–96.View ArticlePubMedPubMed CentralGoogle Scholar
  34. Bennett CL, Ferreira MR, Davis TC, Kaplan J, Weinberger M, Kuzel T, Seday MA, Sartor O. Relation between literacy, race, and stage of presentation among low-income patients with prostate cancer. J Clin Oncol. 1998;16(9):3101–4.PubMedGoogle Scholar
  35. Franks P, Fiscella K, Meldrum S. Racial disparities in the content of primary care office visits. J Gen Intern Med. 2005;20(7):599–603.View ArticlePubMedPubMed CentralGoogle Scholar
  36. Lannin DR, Mathews HF, Mitchell J, Swanson MS, Swanson FH, Edwards MS. Influence of socioeconomic and cultural factors on racial differences in late-stage presentation of breast cancer. JAMA. 1998;279(22):1801–7.View ArticlePubMedGoogle Scholar
  37. Chandwani HS, Strassels SA, Rascati KL, Lawson KA, Wilson JP. Estimates of charges associated with emergency department and hospital inpatient care for opioid abuse-related events. J Pain Palliat Care Pharmacother. 2013;27(3):206–13.View ArticlePubMedGoogle Scholar
  38. Bazargan-Hejazi S, Bazargan M, Hardin E, Bing EG. Alcohol use and adherence to prescribed therapy among under-served Latino and African-American patients using emergency department services. Ethn Dis. 2005;15(2):267–75.PubMedGoogle Scholar
  39. Bazargan-Hejazi S, Bing E, Bazargan M, Der-Martirosian C, Hardin E, Bernstein J, Bernstein E. Evaluation of a brief intervention in an inner-city emergency department. Ann Emerg Med. 2005;46(1):67–76.View ArticlePubMedGoogle Scholar
  40. Lotfipour S, Cisneros V, Anderson CL, Roumani S, Hoonpongsimanont W, Weiss J, Chakravarthy B, Dykzeul B, Vaca F. Assessment of alcohol use patterns among spanish-speaking patients. Subst Abus. 2013;34(2):155–61.View ArticlePubMedPubMed CentralGoogle Scholar
  41. Andrews RM, Moy E. Racial differences in hospital mortality for medical and surgical admissions: variations by patient and hospital characteristics. Ethn Dis. 2015;25(1):90–7.PubMedGoogle Scholar
  42. Onukwugha E, Mullins CD. Racial differences in hospital discharge disposition among stroke patients in Maryland. Med Decis Making. 2007;27(3):233–42.View ArticlePubMedGoogle Scholar
  43. Volpp KG, Stone R, Lave JR, Jha AK, Pauly M, Klusaritz H, Chen H, Cen L, Brucker N, Polsky D. Is thirty-day hospital mortality really lower for black veterans compared with white veterans? Health Serv Res. 2007;42(4):1613–31.View ArticlePubMedPubMed CentralGoogle Scholar

Copyright

© The Author(s). 2016

Advertisement